+ All Categories
Home > Documents > Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Date post: 23-Dec-2015
Category:
Upload: angela-lee
View: 214 times
Download: 1 times
Share this document with a friend
Popular Tags:
44
Skin Cancer Carlos Garcia MD Dermatology at OUHSC conflicts of interest to discl
Transcript
Page 1: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Skin Cancer

Carlos Garcia MD

Dermatology at OUHSC

No conflicts of interest to disclose

Page 2: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Objectives

Identify clinical characteristics ofPrecancerous lesionsCommon skin cancers

Define risk factors for development of skin cancer

Choose appropriate methods for diagnosis and treatment

Page 3: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Precancerous skin lesions

Actinic keratoses

Dysplastic melanocytic nevi

Page 4: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Actinic keratoses

10% risk of malignant transformation

Page 5: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Hypertrophic AK’s

Page 6: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Actinic cheilitis

Page 7: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Liquid nitrogen cryotherapy

Topical therapies

5-FU (Efudex)

Imiquimod (Aldara)

Curettage for hypertrophic lesions

Treatment of AK’s

Page 8: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Residual hypopigmentation

Blister formation

Liquid nitrogenCryotherapy

Page 9: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Topical therapies

Efudex or Aldara

* 3-5 times per week* 6-8 weeks

Page 10: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.
Page 11: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Dysplastic nevi

•Precursors for melanoma

•Markers for melanoma

Page 12: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Treatment of dysplastic nevi

Page 13: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.
Page 14: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Non-melanoma skin cancers (NMSC)

Basal cell carcinoma

Squamous cell carcinoma

Keratoacanthoma

Page 15: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Risk factors for development of BCC and SCC

Fair skin (Fitzpatrick’s types I-III) Blue eyes Red hair

Family history Genetic syndromes

Chronic sun exposure

Old age

Arsenic, tar

Page 16: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Basal cell carcinoma

Page 17: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

BCC- clinical types

Nodular Pigmented Infiltrative

Superficial

Morpheaform

Page 18: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Nodular BCC

Chronic lesion

Easy bleeding

Pearly border

Surface telangiectasias

Head and neck, trunk, and extremities

Page 19: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Pigmented BCC

Similar to nodular but with black discoloration

Melanin deposits

Pigmented races

Face, trunk, and scalp

Page 20: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Superficial BCC

Erythematous scaly plaque

Slow growth

Asymptomatic

Trunk, extremities, face

Page 21: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Morpheaform BCC

Resembles scar

Asymptomatic and slow growing

Ill-defined margins

Marked subclinical extension

Page 22: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

BCC is the most frequent skin cancer (80%)

BCC is 4x more frequent than SCC

Metastases are rare (<1% of cases)

Local destruction of tissue

Page 23: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Treatment of BCC

Curettage electrodessication (ED/C)

Surgical excision Traditional Mohs surgery

Radiation therapy

Topical therapy imiquimod

95% Cure Rate

50-75% Cure Rate

Page 24: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.
Page 25: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Squamous cell carcinoma

Page 26: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

SCC types

In-situ Bowen’s disease Erythroplasia of Queyrat

Invasive SCC Keratoacanthoma

Page 27: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Bowen’s disease

In-situ SCC

Arsenic, HPV 16, radiation

Page 28: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Erythroplasia of Queyrat

In-situ SCC

Uncircumcised men

May progress to invasive SCC

Page 29: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Invasive SCC

Erythematous nodule

Indurated lesion

Sun-exposed skin Men > women

Slow growth

Page 30: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Invasive SCC

Page 31: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Keratoacanthoma

Low grade SCC

Rapid growth over weeks

Trauma, sun exposure, HPV 11 and 16

May progress to invasive SCC

Page 32: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

SCC is locally invasive and destructive

Metastases in 1-3% of cases

To lymph nodes 50-73% survival

Distant sites (lungs) Incurable

Page 33: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Bowen’s disease

Erythroplasia of Queyrat

Efudex or aldara

Liquid nitrogen cryotherapy

Radiation therapy

Curettage electrodessication (ED/C)

Surgical excision

Treatment of SCC

Page 34: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Invasive squamous cell carcinoma

Surgical excision Traditional Mohs surgery

Radiation therapy

Page 35: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.
Page 36: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Malignant Melanoma (MM)

Page 37: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Risk factors- MM Fair skin, red hair, and blue eyes

Intermittent sun exposure Sunburns Tanning beds

Freckles and melanocytic nevi

Family history of melanoma

Page 38: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Clinical types- MM

Superficial spreading melanoma

Lentigo maligna melanoma

Acral lentiginous melanoma Nodular melanoma

Page 39: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

ABCD of Melanoma

Asymmetry

Border irregularity

Color variegation

Diameter >6mm

Page 40: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.
Page 41: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Prognostic features- MM Good prognosis

Breslow < 1mm

Intermediate prognosis Breslow 1-4mm

Bad prognosis Breslow >4mm

Page 42: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Treatment of MM

Surgical excision

In situ = 5 mm margin

Invasive= 1-3 cm depending on Breslow’s depth

Page 43: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Sentinel lymph node biopsy- MM

Recommended for MM with Breslow 1-4mm

Lymphadenectomy for positive nodes

Powerful prognostic feature for disseminated disease

It does not affect survival of patients

Page 44: Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.

Thank you


Recommended